Oxidants not Antioxidants Fight Prostate Cancer - controlled peer reviewed study

[cesanon]

Oxidants not Antioxidants Fight Prostate Cancer - controlled peer reviewed study

All so very interesting. Don't you think?

scitechdaily.com/scientists...

Scientists Have Discovered a Simple Supplement That Causes Prostate Cancer Cells To Self-Destruct

November 29, 20242

Cold Spring Harbor Laboratory has discovered that the pro-oxidant menadione, a vitamin K precursor, slows prostate cancer progression in mice by disrupting cancer cells’ recycling processes, causing them to burst. This breakthrough could offer new hope for treating resistant prostate cancer and even a rare muscle condition in infants.

Menadione, a vitamin K precursor, shows promise in slowing prostate cancer in mice by disrupting cancer cell survival processes, with potential applications for human treatment and myotubular myopathy therapy.

Prostate cancer is a quiet killer. In most men, it’s treatable. While it’s treatable in many men, some cases prove resistant to all current therapies and become highly aggressive. Researchers at Cold Spring Harbor Laboratory (CSHL) have made a new discovery that could lead to a game-changing solution.

CSHL Professor Lloyd Trotman’s lab has found that the pro-oxidant supplement menadione slows prostate cancer progression in mice.

The supplement is a precursor to vitamin K, commonly found in leafy greens. The story begins more than two decades ago.

In 2001, the National Cancer Institute’s SELECT trial sought to determine if an antioxidant vitamin E supplement could successfully treat or prevent prostate cancer. The trial involving 35,000 men was planned to last up to 12 years.

However, after just three years, participants were told to stop taking their supplements. Not only had vitamin E failed to slow or prevent prostate cancer—more men taking the supplement started to get the disease. Seeing these results, Trotman thought, ‘If an antioxidant failed, maybe a pro-oxidant would work.’ His new findings in mice show just that.

How Menadione Targets Cancer Cells

When mice with prostate cancer are given menadione, it messes with the cancer’s survival processes.

Trotman’s team has discovered that menadione kills prostate cancer cells by depleting a lipid called PI(3)P, which works like an ID tag. Without it, the cells stop recycling incoming materials and eventually explode.

“It’s like a transport hub, like JFK. If everything that goes in is immediately de-identified, nobody knows where the airplanes should go next.

New stuff keeps coming in, and the hub starts to swell. This ultimately leads to the cell bursting,” explains Trotman.

This causes the cancer’s progression to slow significantly in mice. Trotman now hopes to see the experiment translated to pilot studies in human prostate cancer patients:

“Our target group would be men who get biopsies and have an early form of the disease diagnosed. We wonder if they start to take the supplement, whether we would be able to slow that disease down.”

If the results hold up in humans, it would mean that men with prostate cancer can enjoy a better quality of life and more time with their families. It could also mean more precious time for children born with an incurable disease.

Reference: “Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function” by Manojit M. Swamynathan, Shan Kuang, Kaitlin E. Watrud, Mary R. Doherty, Charlotte Gineste, Grinu Mathew, Grace Q. Gong, Hilary Cox, Eileen Cheng, David Reiss, Jude Kendall, Diya Ghosh, Colleen R. Reczek, Xiang Zhao, Tali Herzka, Saulė Špokaitė, Antoine N. Dessus, Seung Tea Kim, Olaf Klingbeil, Juan Liu, Dawid G. Nowak, Habeeb Alsudani, Tse-Luen Wee, Youngkyu Park, Francesca Minicozzi, Keith Rivera, Ana S. Almeida, Kenneth Chang, Ram P. Chakrabarty, John E. Wilkinson, Phyllis A. Gimotty, Sarah D. Diermeier, Mikala Egeblad, Christopher R. Vakoc, Jason W. Locasale, Navdeep S. Chandel, Tobias Janowitz, James B. Hicks, Michael Wigler, Darryl J. Pappin, Roger L. Williams, Paolo Cifani, David A. Tuveson, Jocelyn Laporte and Lloyd C. Trotman, 25 October 2024, Science.

DOI: 10.1126/science.adk9167

Funding: National Cancer Institute, Pershing Square Sohn Cancer Research Alliance, IC-MedTech, U.S. Department of Defense, Simons Foundation, AstraZeneca UK, Medical Research Council, Robertson Research Fund

[Schwah]

sounds promising. Three questions.

-Are there any ongoing human trials?

-Are you taking this supplement?

-I am guessing the vast majority of the participants here have no clue what “Menadione, a vitamin K precursor” is or means or how to take it as a supplement. Any guidance out there?

[85745 in reply to Schwah]

Found this article: healthline.com/nutrition/vi...

[cigafred in reply to 85745]

Good find. So we will not find K3 since "Vitamin K3 has been shown to be harmful to humans." But they agree it has potential cancer benefits.

[85745 in reply to cigafred]

More research would be needed before any consideration, Safe for animals but not humans leaves questions in my mind. Many reports of humans having success fighting off there cancers using repurposed drugs behind the back of there doctors knowledge , not endorsing but worth noting.

[j-o-h-n in reply to Schwah]

Menadione is a synthetic form of vitamin K, specifically a precursor of vitamin K2 (menaquinone). It is used in medical and veterinary applications to treat and prevent vitamin K deficiency, which can lead to bleeding disorders due to its role in blood clotting.

Here's a brief overview of its key characteristics:

Chemical Structure and Properties:

Chemical formula: C11H8O2

Synonyms: Vitamin K3 (although this term is not used as frequently today because of the focus on K1 and K2)

Appearance: It is typically a yellow, crystalline powder that is soluble in organic solvents but not in water.

Stability: Menadione is sensitive to light and air, which makes it less stable compared to other forms of vitamin K.

Function and Uses:

Blood Clotting: Menadione plays a vital role in the synthesis of clotting factors in the liver (such as prothrombin), helping to prevent excessive bleeding.

Supplementation: In humans, menadione is sometimes used when vitamin K deficiency is suspected or detected, though other forms like phylloquinone (vitamin K1) or menaquinone (vitamin K2) are preferred for long-term use.

Veterinary Use: Menadione is often used in animal feeds, especially for poultry and livestock, to ensure proper blood clotting.

Side Effects and Concerns:

Toxicity: Menadione has been associated with toxicity when taken in large amounts, including hemolytic anemia (destruction of red blood cells), liver damage, and jaundice. It can also cause allergic reactions.

Controversy: While menadione is effective in treating vitamin K deficiency, it is less commonly used in human medicine today due to the availability of safer and more stable alternatives like vitamin K1 and K2.

Menadione’s role in health is mostly linked to its contribution to blood clotting and its historical use as a vitamin K supplement. However, its potential for toxicity has led to its replacement in many applications by other forms of vitamin K.

Good Luck, Good Health and Good Humor.

j-o-h-n

ChatGPT

[Alicat1]

Vitamin K .... drawing a blank on everyone..... thanks for pointing out this research.

[Lizzo30]

The vitamin E used in the SELECT trial wasn't actually vitamin E it was a synthetic compound but not natural vitamin E

Vitamin E is a very powerful antioxidant that works against reactive oxygen species (ROS)

It's well established that ROS can play a role in the cause and progression of prostate cancer

The SELECT trial has scared people away from vitamin e - one of the most potent anti oxidents we have